Calquence approved in Japan for adults with treatment-naïve chronic lymphocytic leukaemia January 4, 2023
80% ORR reported in Final Cohort of Ph 1 Single Agent Trial of Annamycin for the Treatment of AML December 19, 2022
Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned December 13, 2022
U.S. FDA Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Patients with R/R KMT2A- Rearranged (MLLr) Acute Leukemia December 12, 2022
FDA Approves REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with R/R AML with a Susceptible IDH1 Mutation December 5, 2022
Ph 3 trial of SYK inhibitor, entospletinib, for the treatment of newly diagnosed patients with NPM1-mutated AML to be discontinued November 16, 2022
Positive 1-Year and 2-Year OS Data for Patients with R/R AML in Ph 1 Actimab-A CLAG-M Combo Trial Announced November 16, 2022
Quizartinib Granted Priority Review in the U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AML November 2, 2022
Gilead And MacroGenics Announce Oncology Collaboration To Develop Bispecific Antibodies October 26, 2022
Positive Topline Results Announced from Final PFS Analysis of BRUKINSA vs IMBRUVICA in Ph 3 ALPINE trial in CLL patients October 19, 2022
Ph 1/2 Trial of ABC008 initiated in Patients with T Cell Large Granular Lymphocytic Leukemia October 12, 2022
First Patient Treated in Ph 1/2 Clinical Trial of MB-106 in B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia October 12, 2022
Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development June 14, 2022
MHRA and Research Ethics Committee Approvals Received to Initiate Ph 2B/3 AML Trials of OmnImmune March 24, 2022
